Koch Disruptive Technologies led the molecular diagnostics test developer’s series B round, which will support the progression of its covid-19 test to market.
UK-based molecular diagnostics technology developer Sense Biodetection received $50m yesterday in a series B round led by Koch Disruptive Technologies (KDT), a subsidiary of chemicals and industrial group Koch Industries.
The round also featured Earlybird Health Tech Fund, a fund managed by venture capital firm Earlybird, as well as Cambridge Innovation Capital (CIC), Mercia Asset Management and private investor Jonathan Milner.
Sense is developing handheld molecular diagnostics tests for the detection of viral and bacterial diseases, and its Veros platform…
